Anti-inflammatory effects of the new generation synthetic surfactant CHF5633 on Ureaplasma-induced cytokine responses in human monocytes

References

• Speer CP. Neonatal respiratory distress syndrome: an inflammatory disease? Neonatology. 2011;99(4):316–319.
   PubMed Web of Science ®Google Scholar
• Speer CP, Sweet DG, Halliday HL. Surfactant therapy: past, present and future. Early Hum Dev. 2013;89(Suppl 1):S22–S24.
   Google Scholar
• Curstedt T, Halliday HL, Speer CP. A unique story in neonatal research: the development of a porcine surfactant. Neonatology. 2015;107(4):321–329.
   PubMed Web of Science ®Google Scholar
• Sakonidou S, Dhaliwal J. The management of neonatal respiratory distress syndrome in preterm infants (European Consensus Guidelines-2013 update). Arch Dis Child Educ Pract Ed. 2015;100:257–259.
   PubMed Web of Science ®Google Scholar
• Curstedt T, Calkovska A, Johansson J. New generation synthetic surfactants. Neonatology. 2013;103(4):327–330.
   PubMed Web of Science ®Google Scholar
• Sato A, Ikegami M. SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung. Plos One. 2012;7(7):e39392.
   PubMed Web of Science ®Google Scholar
• Seehase M, Collins JJ, Kuypers E, et al. New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs. Plos One. 2012;7(10):e47631.
   Google Scholar
• Salvesen B, Curstedt T, Mollnes TE, et al. Effects of natural versus synthetic surfactant with SP-B and SP-C analogs in a porcine model of meconium aspiration syndrome. Neonatology. 2014;105(2):128–135.
   PubMed Web of Science ®Google Scholar
• Groneck P, Götze-Speer B, Oppermann M, et al. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics. 1994;93(5):712–718.
   PubMed Web of Science ®Google Scholar
• Jobe AH, Hillman N, Polglase G, et al. Injury and inflammation from resuscitation of the preterm infant. Neonatology. 2008;94(3):190–196.
   PubMed Web of Science ®Google Scholar
• Speer CP. Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology. 2009;95(4):353–361.
   PubMedGoogle Scholar
• Thomas W, Speer CP. Chorioamnionitis: important risk factor or innocent bystander for neonatal outcome? Neonatology. 2011;99(3):177–187.
   PubMed Web of Science ®Google Scholar
• Reyburn B, Martin RJ, Prakash YS, et al. Mechanisms of injury to the preterm lung and airway: implications for long-term pulmonary outcome. Neonatology. 2012;101(4):345–352.
   PubMed Web of Science ®Google Scholar
• Martin RJ, Fanaroff AA. The preterm lung and airway: past, present, and future. Pediatr Neonatol. 2013;54(4):228–234.
   PubMed Web of Science ®Google Scholar
• Goldenberg RL, Andrews WW, Goepfert AR, et al. The Alabama Preterm Birth Study: umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol. 2008;198(1):43 e41–e45.
   Web of Science ®Google Scholar
• Inatomi T, Oue S, Ogihara T, et al. Antenatal exposure to Ureaplasma species exacerbates bronchopulmonary dysplasia synergistically with subsequent prolonged mechanical ventilation in preterm infants. Pediatr Res. 2012;71(3):267–273.
   PubMed Web of Science ®Google Scholar
• Viscardi RM. Perinatal inflammation and lung injury. Semin Fetal Neonatal Med. 2012;17(1):30–35.
   PubMed Web of Science ®Google Scholar
• Lowe J, Watkins WJ, Edwards MO, et al. Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis. Pediatr Infect Dis J. 2014;33(7):697–702.
   PubMed Web of Science ®Google Scholar
• Viscardi RM. Ureaplasma species: role in neonatal morbidities and outcomes. Arch Dis Child Fetal Neonatal Ed. 2014;99(1):F87–F92.
   PubMed Web of Science ®Google Scholar
• Cassell GH, Waites KB, Watson HL, et al. Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns. Clin Microbiol Rev. 1993;6(1):69–87.
   PubMed Web of Science ®Google Scholar
• Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev. 2005;18(4):757–789.
   PubMed Web of Science ®Google Scholar
• Sung T-J, Xiao L, Duffy L, et al. Frequency of ureaplasma serovars in respiratory secretions of preterm infants at risk for bronchopulmonary dysplasia. Pediatr Infect Dis J. 2011;30(5):379–383.
   PubMed Web of Science ®Google Scholar
• Winters AH, Levan TD, Vogel SN, et al. Single nucleotide polymorphism in toll-like receptor 6 is associated with a decreased risk for ureaplasma respiratory tract colonization and bronchopulmonary dysplasia in preterm infants. Pediatr Infect Dis J. 2013;32(8):898–904.
   PubMed Web of Science ®Google Scholar
• Payne MS, Tabone T, Kemp MW, et al. High-resolution melt PCR analysis for genotyping of Ureaplasma parvum isolates directly from clinical samples. J Clin Microbiol. 2014;52(2):599–606.
   PubMed Web of Science ®Google Scholar
• Patterson AM, Taciak V, Lovchik J, et al. Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1-beta and tumor necrosis factor alpha relative to interleukin 6 in tracheal aspirates of preterm infants. Pediatr Infect Dis J. 1998;17(4):321–328.
   PubMed Web of Science ®Google Scholar
• Viscardi RM, Atamas SP, Luzina IG, et al. Antenatal Ureaplasma urealyticum respiratory tract infection stimulates proinflammatory, profibrotic responses in the preterm baboon lung. Pediatr Res. 2006;60(2):141–146.
   PubMed Web of Science ®Google Scholar
• Bose CL, Dammann CE, Laughon MM. Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. Arch Dis Child Fetal Neonatal Ed. 2008;93(6):F455–F461.
   PubMed Web of Science ®Google Scholar
• Murch SH, Costeloe K, Klein NJ, et al. Mucosal tumor necrosis factor-alpha production and extensive disruption of sulfated glycosaminoglycans begin within hours of birth in neonatal respiratory distress syndrome. Pediatr Res. 1996;40(3):484–489.
   PubMed Web of Science ®Google Scholar
• Kolb M, Margetts PJ, Anthony DC, et al. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest. 2001;107(12):1529–1536.
   PubMed Web of Science ®Google Scholar
• Bry K, Whitsett JA, Lappalainen U. IL-1beta disrupts postnatal lung morphogenesis in the mouse. Am J Respir Cell Mol Biol. 2007;36(1):32–42.
   PubMed Web of Science ®Google Scholar
• Kunkel SL, Standiford T, Kasahara K, et al. Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp Lung Res. 1991;17(1):17–23.
   PubMed Web of Science ®Google Scholar
• García-Ramallo E, Marques T, Prats N, et al. Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J Immunol. 2002;169(11):6467–6473.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147(11):3815–3822.
   PubMed Web of Science ®Google Scholar
• Hart PH, Hunt EK, Bonder CS, et al. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol. 1996;157(8):3672–3680.
   PubMed Web of Science ®Google Scholar
• Sabat R, Grutz G, Warszawska K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21(5):331–344.
   PubMed Web of Science ®Google Scholar
• Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23–63.
   PubMed Web of Science ®Google Scholar
• Jones CA, Cayabyab RG, Kwong KY, et al. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr Res. 1996;39(6):966–975.
   PubMed Web of Science ®Google Scholar
• Speer CP. Pulmonary inflammation and bronchopulmonary dysplasia. J Perinatol. 2006;26(Suppl 1):S57–S62. discussion S63–54.
   Google Scholar
• Kollmann TR, Crabtree J, Rein-Weston A, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol. 2009;183(11):7150–7160.
   PubMed Web of Science ®Google Scholar
• Caron JE, La Pine TR, Augustine NH, et al. Multiplex analysis of toll-like receptor-stimulated neonatal cytokine response. Neonatology. 2010;97(3):266–273.
   PubMed Web of Science ®Google Scholar
• Glaser K, Speer CP. Toll-like receptor signaling in neonatal sepsis and inflammation: a matter of orchestration and conditioning. Expert Rev Clin Immunol. 2013;9(12):1239–1252.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.
   PubMed Web of Science ®Google Scholar
• Liew FY, Xu D, Brint EK, et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005;5(6):446–458.
   PubMed Web of Science ®Google Scholar
• Benjamin JT, Smith RJ, Halloran BA, et al. FGF-10 is decreased in bronchopulmonary dysplasia and suppressed by Toll-like receptor activation. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):L550–L558.
   Google Scholar
• Chaudhuri N, Whyte MK, Sabroe I. Reducing the toll of inflammatory lung disease. Chest. 2007;131(5):1550–1556.
   PubMed Web of Science ®Google Scholar
• Lavoie PM, Ladd M, Hirschfeld AF, et al. Influence of common non-synonymous Toll-like receptor 4 polymorphisms on bronchopulmonary dysplasia and prematurity in human infants. Plos One. 2012;7(2):e31351.
   Google Scholar
• Prince LS, Dieperink HI, Okoh VO, et al. Toll-like receptor signaling inhibits structural development of the distal fetal mouse lung. Dev Dyn. 2005;233(2):553–561.
   PubMed Web of Science ®Google Scholar
• He Z, Zhu Y, Jiang H. Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fibrosis during acute lung injury induced by lipopolysaccharide: an experimental study. Respir Res. 2009;10:126.
   PubMed Web of Science ®Google Scholar
• Henning LN, Azad AK, Parsa KV, et al. Pulmonary surfactant protein A regulates TLR expression and activity in human macrophages. J Immunol. 2008;180(12):7847–7858.
   PubMed Web of Science ®Google Scholar
• Bersani I, Speer CP, Kunzmann S. Surfactant proteins A and D in pulmonary diseases of preterm infants. Expert Rev Anti Infect Ther. 2012;10(5):573–584.
   PubMed Web of Science ®Google Scholar
• Bersani I, Kunzmann S, Speer CP. Immunomodulatory properties of surfactant preparations. Expert Rev Anti Infect Ther. 2013;11(1):99–110.
   PubMed Web of Science ®Google Scholar
• Nguyen HA, Rajaram MV, Meyer DA, et al. Pulmonary surfactant protein A and surfactant lipids upregulate IRAK-M, a negative regulator of TLR-mediated inflammation in human macrophages. Am J Physiol Lung Cell Mol Physiol. 2012;303(7):L608–L616.
   PubMedGoogle Scholar
• Wesche H, Gao X, Li X, et al. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem. 1999;274(27):19403–19410.
   PubMed Web of Science ®Google Scholar
• Glaser K, Fehrholz M, Curstedt T, et al. Effects of the new generation synthetic reconstituted surfactant CHF5633 on pro- and anti-inflammatory cytokine expression in native and LPS-stimulated adult CD14+ monocytes. Plos One. 2016;11(1):e0146898.
   Google Scholar
• Glaser K, Fehrholz M, Papsdorf M, et al. The new generation synthetic reconstituted surfactant CHF5633 suppresses LPS-induced cytokine responses in human neonatal monocytes. Cytokine. 2016;86:119–123.
   PubMed Web of Science ®Google Scholar
• Fehrholz M, Glaser K, Seidenspinner S, et al. Impact of the new generation reconstituted surfactant CHF5633 on human CD4+ Lymphocytes. Plos One. 2016;11(4):e0153578.
   Google Scholar
• Mobius N, Brenneisen W, Schaeffer A, et al. Protocol for the rapid detection of the urogenital tract mollicutes and Chlamydia with concomitant LGV-(sub)typing. Methods Mol Biol. 2012;903:235–253.
   PubMedGoogle Scholar
• Glaser K, Fehrholz M, Seidenspinner S, et al. Pitfalls in flow cytometric analyses of surfactant-exposed human leukocytes. Immunol Lett. 2015;166(1):19–27.
   PubMed Web of Science ®Google Scholar
• Anderson P. Post-transcriptional control of cytokine production. Nat Immunol. 2008;9(4):353–359.
   PubMed Web of Science ®Google Scholar
• Cox C, Saxena N, Watt AP, et al. The common vaginal commensal bacterium Ureaplasma parvum is associated with chorioamnionitis in extreme preterm labor. J Matern Fetal Neonatal Med. 2016;29(22):3646-3651.
   Web of Science ®Google Scholar
• Manimtim WM, Hasday JD, Hester L, et al. Ureaplasma urealyticum modulates endotoxin-induced cytokine release by human monocytes derived from preterm and term newborns and adults. Infect Immun. 2001;69(6):3906–3915.
   PubMed Web of Science ®Google Scholar
• Tsao PN. Pulmonary drug delivery by surfactant. Pediatr Neonatol. 2015;56(1):3–4.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri B, Abraham S, Bonfield TL, et al. Surfactant blocks lipopolysaccharide signaling by inhibiting both mitogen-activated protein and IkappaB kinases in human alveolar macrophages. Am J Respir Cell Mol Biol. 2004;30(2):228–232.
   PubMed Web of Science ®Google Scholar
• Thomassen MJ, Antal JM, Connors MJ, et al. Characterization of exosurf (surfactant)-mediated suppression of stimulated human alveolar macrophage cytokine responses. Am J Respir Cell Mol Biol. 1994;10(4):399–404.
   PubMed Web of Science ®Google Scholar
• Thomassen MJ, Meeker DP, Antal JM, et al. Synthetic surfactant (Exosurf) inhibits endotoxin-stimulated cytokine secretion by human alveolar macrophages. Am J Respir Cell Mol Biol. 1992;7(3):257–260.
   PubMed Web of Science ®Google Scholar